<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03988946</url>
  </required_header>
  <id_info>
    <org_study_id>CP21549</org_study_id>
    <nct_id>NCT03988946</nct_id>
  </id_info>
  <brief_title>Cephea Transseptal Mitral Valve System FIH</brief_title>
  <official_title>Cephea Mitral Valve and Transseptal Delivery System FIH</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cephea Valve Technologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cephea Valve Technologies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety and performance of the Cephea Transseptal Mitral Valve System for the
      treatment of symptomatic moderate to severe degenerative or functional mitral regurgitation,
      in patients who are poor candidates for surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as measured by freedom from major adverse events</measure>
    <time_frame>30 days</time_frame>
    <description>Freedom from major adverse events, including:
All-cause mortality
Disabling stroke
Myocardial infarction
Renal failure requiring dialysis
Life-threatening bleeding
Any valve-related dysfunction, migration, thrombosis, or other complication requiring surgery or repeat intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Performance</measure>
    <time_frame>30 days</time_frame>
    <description>Reduction in mitral regurgitation to â‰¤1+</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Mitral Regurgitation</condition>
  <arm_group>
    <arm_group_label>Transcatheter Mitral Valve Replacement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Replacement valve delivered through a transfemoral access and transseptal approach</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcatheter Mitral Valve Replacement via Transseptal Access</intervention_name>
    <description>The Cephea Transseptal Mitral Valve System is intended for use in symptomatic patients with moderate to severe degenerative or functional mitral regurgitation, who are poor candidates for surgery and who are anatomically eligible for the treatment.</description>
    <arm_group_label>Transcatheter Mitral Valve Replacement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        MVARC
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helen J Scotch</last_name>
    <role>Study Director</role>
    <affiliation>Cephea Valve Technologies</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Vincent's Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 10, 2019</study_first_submitted>
  <study_first_submitted_qc>June 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2019</study_first_posted>
  <last_update_submitted>January 21, 2020</last_update_submitted>
  <last_update_submitted_qc>January 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

